AZ partners with Galderma on psoriasis research
pharmafile | March 9, 2011 | News story | Research and Development | AZ, AstraZeneca, Galderma, dermatology, psoriasis
AstraZeneca has signed a five-year deal with dermatology specialist Galderma Pharma to develop new treatments for conditions including psoriasis.
It is an effort by AstraZeneca to expand its existing work into new areas and will see Galderma receive exclusive access to AZ compounds to develop dermatological indications.
The companies said those identified so far come from a broad spectrum, taking in AstraZeneca’s oncology, inflammation and central nervous system portfolios, but did not disclose any financial details for their agreement.
The compounds will undergo pre-clinical testing to determine which will progress into development.
In addition to psoriasis, R&D efforts will focus on acne and atopic dermatitis. The agreement “will complement Galderma’s internal R&D efforts and significantly enhance our ability to make important new discoveries,” says Galderma chief scientific officer Alain Jacot.
Galderma’s current products also treat rosacea, onychomycosis, steroid-responsive dermatoses, pigmentary disorders and skin cancer.
“This partnership is an example of how we are leveraging our science in new and creative ways through collaborations with recognised experts outside of AstraZeneca’s core therapy areas,” says Clive Morris, head of new opportunities at the company’s innovative medicines unit.
“Partnering with Galderma, a world-leader in dermatology, is the most efficient and effective way to unlock the potential of our compounds in this rapidly evolving disease area,” he added.
Founded in 1981, Galderma has 3,200 employees in 31 affiliates and manufacturing plants in France, Brazil and Canada.
Its laboratory in Sophia-Antipolis, France, is one of the largest R&D facilities in the world dedicated exclusively to dermatology.
Galderma’s £23 million UK arm takes in prescription products, and corrective and aesthetic procedures, as well as OTC brands.
“Galderma is committed to discovering, developing and delivering innovative solutions for dermatology patients and physicians,” concludes Jacot.
Existing brands include Epiduo, Oracea, Clobex, Azzalure/Dysport, Differin, Cetaphil, Loceryl, Rozex/MetroGel, Silkis/Vectical, Metvix, Tri-Luma and Emervel.
Adam Hill
Related Content
Chronic spontaneous urticaria – the impact on patient quality of life, ongoing developments in treatments and the importance of greater awareness
The current forms of immunotherapy, how T cell therapy works and what the future holds
NICE recommends Benralizumab for Rare Form of Vasculitis
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as …
NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer
AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence …
